Ovid Therapeutics (OVID) Other Gross PP&E Adjustments (2020 - 2025)
Ovid Therapeutics (OVID) has disclosed Other Gross PP&E Adjustments for 6 consecutive years, with -$10.4 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Other Gross PP&E Adjustments rose 10.24% year-over-year to -$10.4 million, compared with a TTM value of -$10.4 million through Sep 2025, up 10.24%, and an annual FY2024 reading of -$16.8 million, up 14.65% over the prior year.
- Other Gross PP&E Adjustments was -$10.4 million for Q3 2025 at Ovid Therapeutics, up from -$10.7 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$1.2 million in Q3 2021 and bottomed at -$19.7 million in Q4 2023.
- Average Other Gross PP&E Adjustments over 5 years is -$12.0 million, with a median of -$12.1 million recorded in 2024.
- The sharpest move saw Other Gross PP&E Adjustments skyrocketed 44.06% in 2021, then plummeted 1187.73% in 2022.
- Year by year, Other Gross PP&E Adjustments stood at -$4.2 million in 2021, then tumbled by 356.91% to -$19.0 million in 2022, then decreased by 3.57% to -$19.7 million in 2023, then rose by 14.65% to -$16.8 million in 2024, then skyrocketed by 38.19% to -$10.4 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for OVID at -$10.4 million in Q3 2025, -$10.7 million in Q2 2025, and -$11.0 million in Q1 2025.